{"id":4161,"date":"2026-11-09T08:00:00","date_gmt":"2026-11-09T12:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=4161"},"modified":"2026-11-09T21:32:35","modified_gmt":"2026-11-10T01:32:35","slug":"allo-329-first-clinical-dataset-in-autoimmune-disease","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=4161","title":{"rendered":"ALLO 329 First Clinical Dataset in Autoimmune Disease"},"content":{"rendered":"<p><img fetchpriority=\"high\" decoding=\"async\" width=\"768\" height=\"432\" src=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261109_Allogene_Therapeutics_Technology_and_Modalities-768x432.png\" alt=\"\" class=\"attachment-medium_large size-medium_large wp-image-4170\" srcset=\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261109_Allogene_Therapeutics_Technology_and_Modalities-768x432.png 768w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261109_Allogene_Therapeutics_Technology_and_Modalities-300x169.png 300w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261109_Allogene_Therapeutics_Technology_and_Modalities-1024x576.png 1024w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261109_Allogene_Therapeutics_Technology_and_Modalities-1536x864.png 1536w, https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/11\/20261109_Allogene_Therapeutics_Technology_and_Modalities.png 1672w\" sizes=\"(max-width: 768px) 100vw, 768px\" \/><\/p>\n<p><strong>Company<\/strong><\/p>\n<p>Allogene Therapeutics<\/p>\n<p><strong>Event Type<\/strong><\/p>\n<p>First-in-human Phase 1 data (RESOLUTION)<\/p>\n<p><strong>Modality<\/strong><\/p>\n<p>Allogeneic CAR T<\/p>\n<p><strong>Asset<\/strong><\/p>\n<p>ALLO-329<\/p>\n<p><strong>Target<\/strong><\/p>\n<p>CD19; CD70<\/p>\n<p><strong>Disease Area<\/strong><\/p>\n<p>Systemic sclerosis; myositis; lupus<\/p>\n<h4>Summary<\/h4>\n<p>Allogene disclosed first-in-human Phase 1 RESOLUTION data for its CD19\/CD70 allogeneic CAR T therapy. Skin scores improved in eight of ten assessed systemic sclerosis patients, including recipients without chemotherapy lymphodepletion. The small, uncontrolled, dose-escalating dataset tests feasibility and does not establish comparative efficacy or a lymphodepletion-free regimen.<\/p>\n<p>The November 9 release reports a September 21 cutoff. Eighteen patients across systemic sclerosis, myositis and lupus completed the 28-day dose-limiting-toxicity period. No dose-limiting toxicity, ICANS, IEC-HS, graft-versus-host disease or grade 3 or worse CRS was reported. Four patients had CRS, three grade 1 and one grade 2. In ten skin-predominant systemic sclerosis patients, eight maintained an mRSS improvement of at least five points and nine remained off background immunosuppression at cutoff. Six participants received no lymphodepletion; cohorts varied in dose, conditioning, diagnosis and observation time.<\/p>\n<h4>Deep Analysis<\/h4>\n<p>ALLO-329 combines CD19 B-cell targeting with CD70 targeting of activated immune cells. CD70-mediated depletion of host alloreactive cells is proposed to reduce rejection and conventional fludarabine\/cyclophosphamide exposure. The observation of clinical activity without lymphodepletion is translationally relevant because conditioning toxicity and operational complexity are major constraints on autoimmune cell therapy. Yet a six-person no-conditioning safety cohort and mixed dosing cannot establish noninferiority to conditioned treatment, durable CAR persistence, organ protection or disease modification. mRSS is clinically relevant but observer-sensitive; baseline trajectory, concomitant medication taper, organ involvement, cell expansion and longer follow-up are necessary. Cross-trial comparisons with autologous CD19 CAR T are invalid without matched severity and endpoint timing. Manufacturing yield, release consistency, allorejection, infection risk and late cytopenias remain central scale and safety questions.<\/p>\n<h4>Company and Product Background<\/h4>\n<p>Allogene develops donor-derived engineered T cells. ALLO-329 is an investigational dual CD19\/CD70 CAR T candidate. Systemic sclerosis is an autoimmune fibrotic disorder that can damage skin, lungs and other organs; B-cell depletion and broader immune reset are proposed treatment mechanisms.<\/p>\n<h4>Signal Extraction<\/h4>\n<ul>\n<li><strong>Interpretation A:<\/strong> CD70 targeting permits useful cell activity with reduced conditioning; activity observed across conditioning approaches supports feasibility. Contradiction: numbers and follow-up are too small to isolate CD70 contribution.<\/li>\n<li><strong>Interpretation B:<\/strong> selected patients or background disease variability explain part of skin-score improvement; single-arm design supports this concern. Contradiction: several patients had multidimensional changes, although these remain uncontrolled.<\/li>\n<li><strong>Upgrade:<\/strong> with prespecified conditioning comparisons, sustained CAR kinetics, organ endpoints and replicated response; <strong>Downgrade:<\/strong> with attrition, loss of response or serious late toxicity; <strong>Falsification:<\/strong> a conditioning-sparing claim if controlled exposure and clinical activity prove materially worse without conditioning.<\/li>\n<\/ul>\n<h4>InSilens Take<\/h4>\n<p>This is an important early platform test for allogeneic autoimmune CAR T and conditioning reduction. The current evidence supports continued dose and regimen study, not a conclusion that lymphodepletion can be eliminated or that the product is clinically superior.<\/p>\n<h4>Signal Assessment<\/h4>\n<p>Signal Importance: 4 of 5. Signal Direction: uncertain. Confidence in Facts: high for disclosed observations. Confidence in Interpretation: low to moderate.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Allogene disclosed first-in-human Phase 1 RESOLUTION data for its CD19\/CD70 allogeneic CAR T therapy. Skin scores improved in eight of ten assessed systemic sclerosis patients, including recipients without chemotherapy lymphodepletion. The small, uncontrolled, dose-escalating&#8230;<\/p>\n","protected":false},"author":1,"featured_media":4170,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[1410,129,34],"class_list":["post-4161","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology-modalities","tag-allo-329","tag-allogene-therapeutics","tag-systemic-sclerosis"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4161","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4161"}],"version-history":[{"count":1,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4161\/revisions"}],"predecessor-version":[{"id":4171,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/4161\/revisions\/4171"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/4170"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4161"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4161"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4161"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}